Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Acta Pharmacol Sin ; 45(4): 790-802, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38191913

ABSTRACT

Osteoporosis results from overactivation of osteoclasts. There are currently few drug options for treatment of this disease. Since the successful development of allosteric inhibitors, phosphatases have become attractive therapeutic targets. Protein phosphatase 1, regulatory subunit 15 A (PPP1R15A), is a stress-responsive protein, which promotes the UPR (unfolded protein response) and restores protein homeostasis. In this study we investigated the role of PPP1R15A in osteoporosis and osteoclastogenesis. Ovariectomy (OVX)-induced osteoporosis mouse model was established, osteoporosis was evaluated in the left femurs using micro-CT. RANKL-stimulated osteoclastogenesis was used as in vitro models. We showed that PPP1R15A expression was markedly increased in BMMs derived from OVX mice and during RANKL-induced osteoclastogenesis in vitro. Knockdown of PPP1R15A or application of Sephin1 (a PPP1R15A allosteric inhibitor in a phase II clinical trial) significantly inhibited osteoclastogenesis in vitro. Sephin1 (0.78, 3.125 and 12.5 µM) dose-dependently mitigated the changes in NF-κB, MAPK, and c-FOS and the subsequent nuclear factor of activated T cells 1 (NFATc1) translocation in RANKL-stimulated BMMs. Both Sephin1 and PPP1R15A knockdown increased the phosphorylated form of eukaryotic initiation factor 2α (eIF2α); knockdown of eIF2α reduced the inhibitory effects of Sephin1 on NFATc1-luc transcription and osteoclast formation. Furthermore, Sephin1 or PPP1R15A knockdown suppressed osteoclastogenesis in CD14+ monocytes from osteoporosis patients. In OVX mice, injection of Sephin1 (4, 8 mg/kg, i.p.) every two days for 6 weeks significantly inhibited bone loss, and restored bone destruction and decreased TRAP-positive cells. This study has identified PPP1R15A as a novel target for osteoclast differentiation, and genetic inhibition or allosteric inhibitors of PPP1R15A, such as Sephin1, can be used to treat osteoporosis. This study revealed that PPP1R15A expression was increased in osteoporosis in both human and mice. Inhibition of PPP1R15A by specific knockdown or an allosteric inhibitor Sephin1 mitigated murine osteoclast formation in vitro and attenuated ovariectomy-induced osteoporosis in vivo. PPP1R15A inhibition also suppressed pathogenic osteoclastogenesis in CD14+ monocytes from osteoporosis patients. These results identify PPP1R15A as a novel regulator of osteoclastogenesis and a valuable therapeutic target for osteoporosis.


Subject(s)
Guanabenz , Osteoporosis , Animals , Female , Humans , Mice , Cell Differentiation , Guanabenz/analogs & derivatives , Guanabenz/therapeutic use , NF-kappa B/metabolism , NFATC Transcription Factors/metabolism , Osteoclasts , Osteogenesis , Osteoporosis/drug therapy , Ovariectomy , Protein Phosphatase 1/metabolism , Protein Phosphatase 1/pharmacology , RANK Ligand/metabolism
2.
Neurochem Int ; 162: 105438, 2023 01.
Article in English | MEDLINE | ID: mdl-36351540

ABSTRACT

Dopamine regulates psychomotor function by D1 receptor/PKA-dependent phosphorylation of DARPP-32. DARPP-32, phosphorylated at Thr34 by PKA, inhibits protein phosphatase 1 (PP1), and amplifies the phosphorylation of other PKA/PP1 substrates following D1 receptor activation. In addition to the D1 receptor/PKA/DARPP-32 signaling pathway, D1 receptor stimulation is known to activate Rap1/ERK signaling. Rap1 activation is mediated through the phosphorylation of Rasgrp2 (guanine nucleotide exchange factor; activation) and Rap1gap (GTPase-activating protein; inhibition) by PKA. In this study, we investigated the role of PP1 inhibition by phospho-Thr34 DARPP-32 in the D1 receptor-induced phosphorylation of Rasgrp2 and Rap1gap at PKA sites. The analyses in striatal and NAc slices from wild-type and DARPP-32 knockout mice revealed that the phosphorylation of Rasgrp2 at Ser116/Ser117 and Ser586, but not of Rasgrp2 at Ser554 or Rap1gap at Ser441 or Ser499 induced by a D1 receptor agonist, is under the control of the DARPP-32/PP1. The results were supported by pharmacological analyses using a selective PP1 inhibitor, tautomycetin. In addition, analyses using a PP1 and PP2A inhibitor, okadaic acid, revealed that all sites of Rasgrp2 and Rap1gap were regulated by PP2A. Thus, the interactive machinery of DARPP-32/PP1 may contribute to efficient D1 receptor signaling via Rasgrp2/Rap1 in the striatum.


Subject(s)
Corpus Striatum , Neostriatum , Animals , Mice , Protein Phosphatase 1/metabolism , Protein Phosphatase 1/pharmacology , Corpus Striatum/metabolism , Neostriatum/metabolism , Dopamine and cAMP-Regulated Phosphoprotein 32/metabolism , Signal Transduction , Phosphorylation , Receptors, Dopamine D1/metabolism
3.
J Pharmacol Sci ; 123(3): 279-83, 2013.
Article in English | MEDLINE | ID: mdl-24152962

ABSTRACT

Stimulation of ß-adrenergic receptors in cardiac myocytes activates cyclic AMP-dependent protein kinase A (PKA). PKA-mediated phosphorylation of myofibrils decreases their longitudinal stiffness, but its effect on transverse stiffness is not fully understood. We thus examined the effects of PKA treatment on the transverse stiffness of cardiac myofibrils by atomic force microscopy and determined the phosphorylation levels of myofibril components by SDS-PAGE. Transverse stiffness was significantly decreased by PKA treatment concomitantly with increased phosphorylation of troponin I, myosin-binding protein C, and titin (also called connectin). Subsequent treatment with protein phosphatase 1 abrogated these PKA-mediated effects.


Subject(s)
Cyclic AMP-Dependent Protein Kinases/metabolism , Cyclic AMP-Dependent Protein Kinases/pharmacology , Elasticity/drug effects , Myocytes, Cardiac/metabolism , Myocytes, Cardiac/physiology , Myofibrils/physiology , Carrier Proteins/metabolism , Cells, Cultured , Connectin/metabolism , Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors , Cyclic AMP-Dependent Protein Kinases/physiology , Electrophoresis, Polyacrylamide Gel , Humans , Microscopy, Atomic Force , Myocytes, Cardiac/ultrastructure , Myofibrils/metabolism , Myofibrils/ultrastructure , Phosphorylation , Protein Phosphatase 1/pharmacology , Receptors, Adrenergic, beta , Troponin I/metabolism
4.
J Am Chem Soc ; 133(22): 8392-5, 2011 Jun 08.
Article in English | MEDLINE | ID: mdl-21462979

ABSTRACT

Micelles were prepared from polymer-peptide block copolymer amphiphiles containing substrates for protein kinase A, protein phosphatase-1, and matrix metalloproteinases 2 and 9. We examine reversible switching of the morphology of these micelles through a phosphorylation-dephosphorylation cycle and study peptide-sequence directed changes in morphology in response to proteolysis. Furthermore, the exceptional uniformity of these polymer-peptide particles makes them amenable to cryo-TEM reconstruction techniques lending insight into their internal structure.


Subject(s)
Cyclic AMP-Dependent Protein Kinases/pharmacology , Matrix Metalloproteinase 2/pharmacology , Matrix Metalloproteinase 9/pharmacology , Micelles , Nanoparticles/chemistry , Protein Phosphatase 1/pharmacology , Cyclic AMP-Dependent Protein Kinases/chemistry , Matrix Metalloproteinase 2/chemistry , Matrix Metalloproteinase 9/chemistry , Microscopy, Electron, Transmission , Models, Molecular , Molecular Structure , Particle Size , Protein Phosphatase 1/chemistry
5.
Nat Cell Biol ; 11(5): 644-51, 2009 May.
Article in English | MEDLINE | ID: mdl-19396163

ABSTRACT

Loss of cell division cycle 2 (Cdc2, also known as Cdk1) activity after cyclin B degradation is necessary, but not sufficient, for mitotic exit. Proteins phosphorylated by Cdc2 and downstream mitotic kinases must be dephosphorylated. We report here that protein phosphatase-1 (PP1) is the main catalyst of mitotic phosphoprotein dephosphorylation. Suppression of PP1 during early mitosis is maintained through dual inhibition by Cdc2 phosphorylation and the binding of inhibitor-1. Protein kinase A (PKA) phosphorylates inhibitor-1, mediating binding to PP1. As Cdc2 levels drop after cyclin B degradation, auto-dephosphorylation of PP1 at its Cdc2 phosphorylation site (Thr 320) allows partial PP1 activation. This promotes PP1-regulated dephosphorylation at the activating site of inhibitor-1 (Thr 35) followed by dissociation of the inhibitor-1-PP1 complex and then full PP1 activation to promote mitotic exit. Thus, Cdc2 both phosphorylates multiple mitotic substrates and inhibits their PP1-mediated dephosphorylation.


Subject(s)
Cell Cycle Proteins/metabolism , Mitosis/physiology , Phosphoproteins/metabolism , Protein Phosphatase 1/metabolism , Proteins/metabolism , 8-Bromo Cyclic Adenosine Monophosphate/pharmacology , Animals , CDC2 Protein Kinase , Cell Cycle/physiology , Cell Cycle Proteins/antagonists & inhibitors , Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors , Cyclic AMP-Dependent Protein Kinases/metabolism , Cyclin B/metabolism , Cyclin B/pharmacology , Cyclin-Dependent Kinases , HeLa Cells , Humans , Models, Biological , Okadaic Acid/pharmacology , Oocytes/drug effects , Oocytes/metabolism , Phosphorylation , Protein Binding/physiology , Protein Kinase Inhibitors/pharmacology , Protein Kinases/metabolism , Protein Phosphatase 1/antagonists & inhibitors , Protein Phosphatase 1/pharmacology , Proteins/pharmacology , Purines/pharmacology , Roscovitine , Threonine/metabolism , Xenopus Proteins/antagonists & inhibitors , Xenopus Proteins/metabolism , Xenopus laevis
6.
ChemMedChem ; 3(12): 1878-92, 2008 Dec.
Article in English | MEDLINE | ID: mdl-19025735

ABSTRACT

Cantharidin (1) and its derivatives are of significant interest as serine/threonine protein phosphatase 1 and 2A inhibitors. Additionally, compounds of this type have displayed growth inhibition of various tumour cell lines. To further explore both of these inhibition pathways, a number of amide-acid norcantharidin analogues (15-26) were prepared. Compounds 23 and 24, containing two carboxylic acid residues, showed good PP1 and PP2A activity, with IC(50) values of approximately 15 and approximately 3 mum, respectively. Substituted aromatic amide analogues 45, 48, 49, 52, 53, and 54 also displayed good PP1 and PP2A inhibition, with IC(50) values in the range of 15-10 microM (PP1) and 11-5 microM (PP2A). However, bulky ortho substituents on the aromatic ring caused the aromatic ring to be skewed from the NCO planarity, leading to a decrease in PP1 and PP2A inhibition. A number of analogues, 20, 22, 25 and 46, showed excellent tumour growth inhibition, with 46 in particular being more potent than the lead, norcantharidin 2.


Subject(s)
Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/pharmacology , Bridged Bicyclo Compounds, Heterocyclic/chemistry , Cantharidin/analogs & derivatives , Protein Phosphatase 1/antagonists & inhibitors , Protein Phosphatase 2/antagonists & inhibitors , Animals , Antineoplastic Agents/chemistry , Bridged Bicyclo Compounds, Heterocyclic/chemical synthesis , Bridged Bicyclo Compounds, Heterocyclic/pharmacology , Cantharidin/chemical synthesis , Cantharidin/pharmacology , Cell Line , Crystallography, X-Ray , Drug Screening Assays, Antitumor , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , Humans , Inhibitory Concentration 50 , Mice , Protein Phosphatase 1/pharmacology , Protein Phosphatase 2/pharmacology , Structure-Activity Relationship , Tumor Cells, Cultured
7.
J Mol Biol ; 380(5): 789-98, 2008 Jul 25.
Article in English | MEDLINE | ID: mdl-18572192

ABSTRACT

The apolipoprotein A5 gene (APOA5) is a key player in determining triglyceride concentrations in humans and mice. Since diabetes is often associated with hypertriglyceridemia, this study explores whether APOA5 gene expression is regulated by alteration in glucose homeostasis and the related pathways. d-Glucose activates APOA5 gene expression in a time- and dose-dependent manner in hepatocytes, and the glycolytic pathway involved was determined using d-glucose analogues and metabolites. Together, transient transfections, electrophoretic mobility shift assays and chromatin immunoprecipitation assays show that this regulation occurs at the transcriptional level through an increase of USF1/2 binding to an E-box in the APOA5 promoter. We show that this phenomenon is not due to an increase of mRNA or protein expression levels of USF. Using protein phosphatases 1 and 2A inhibitor, we demonstrate that d-glucose regulates the APOA5 gene via a dephosphorylation mechanism, resulting in an enhanced USF1/2-promoter binding. Last, subsequent suppressions of USF1/2 and phosphatases mRNA through siRNA gene silencing abolished the regulation. We demonstrate that the APOA5 gene is up regulated by d-glucose and USF through phosphatase activation. These findings may provide a new cross-talk between glucose and lipid metabolism.


Subject(s)
Apolipoproteins A/metabolism , Gene Expression Regulation/drug effects , Glucose/pharmacology , Animals , Apolipoprotein A-V , Apolipoproteins A/genetics , Cell Line , Cell Line, Tumor , Dose-Response Relationship, Drug , Enzyme Activation/drug effects , Enzyme Inhibitors/pharmacology , Glycolysis , Hepatocytes/drug effects , Hepatocytes/metabolism , Humans , Promoter Regions, Genetic , Protein Binding , Protein Phosphatase 1/pharmacology , Protein Phosphatase 2/pharmacology , RNA, Messenger/metabolism , Rats , Time Factors , Transcription, Genetic , Upstream Stimulatory Factors/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...